Short-Course Antibiotics for Childhood Pneumonia

Friday, Oct. 23, 2020 Childhood Pneumonia Study Shows Short-Course Antibiotics Superior to Standard of Care A NIAID-sponsored randomized, double-blind, placebo-controlled trial study has shown that short-course (five day) antibiotic treatment is superior to standard (10 day) treatment of community-acquired pneumonia (CAP) in children age 6 months to 5 years. Both treatment strategies were effective in treating CAP.  However, scientists have come to recognize that using only the amount of antibiotics that is needed—and no more—not only is good for patients but also helps conserve the long-term effectiveness of available antibiotics. The results of the study were presented during the ID Week 2020 online conference. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107